ArticleCureus2026
Upper Gastrointestinal Bleeding Due to Ruptured Gastric Varices: A Diagnostic Challenge.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric variceal (GV) bleeding is a life-threatening complication of portal hypertension, most commonly associated with cirrhosis. However, non-cirrhotic portal hypertension (NCPH) is an important and under-recognized cause, with portosinusoidal vascular disorder (PSVD) being a key entity, particularly in patients exposed to chemotherapy. A 39-year-old man with a history of childhood neuroblastoma treated with dacarbazine, cyclophosphamide, doxorubicin, and vincristine presented with hematemesis and syncope. On admission, he was hypotensive and tachycardic. Laboratory tests revealed anemia (hemoglobin 6.9 g/dL), preserved liver function, and normal coagulation. Endoscopy showed a fundal GV with a "white nipple" sign. He received prompt vasoactive therapy, endoscopic cyanoacrylate injection, blood transfusion, and prophylaxis with ceftriaxone. Despite initial stabilization, bleeding recurred after terlipressin discontinuation, requiring a new endoscopic intervention. Common causes of cirrhosis were excluded. Imaging showed no parenchymal or vascular abnormalities. Elastography revealed normal liver stiffness (5.3 kPa) and elevated splenic stiffness (33.8 kPa). Hepatic angiography determined a portosystemic gradient of 15 mmHg. Liver biopsy demonstrated vascular changes consistent with PSVD. Extensive workup excluded other etiologies, leading to a final diagnosis of NCPH due to PSVD likely secondary to prior chemotherapy. The patient was started on a non-selective beta-blocker, with no further bleeding during follow-up. This case highlights the diagnostic and therapeutic challenges of GV bleeding in NCPH and underscores the importance of a systematic and multidisciplinary workup to identify PSVD. A detailed history, including prior chemotherapy exposure, is crucial for appropriate management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.